IP Library Granted Patent US 12,133,842
Granted Patent B2
US 12,133,842 · App. 17/552,872 · Granted Nov 5, 2024

Stable preservative-free mydriatic and anti-inflammatory solutions for injection

Inventors: Gregory A. Demopulos (Mercer Island, WA); Hui-rong Shen (Bothell, WA); Clark E. Tedford (Poulsbo, WA)
Assignee: Rayner Intraocular Lenses Limited
A61K31/407A61K9/0048A61K31/137A61K31/138
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,133,842
App. No.
17/552,872
Granted
Nov 5, 2024
Kind
B2
Abstract

The present invention relates to stable, preservative- and antioxidant-free liquid formulations of phenylephrine and ketorolac for injection.

Claims (10)

1. A liquid pharmaceutical dosage form comprising phenylephrine, ketorolac, a buffer system, an intraocular irrigation carrier and an inert gas overlay in a single-use container, wherein the phenylephrine is included at a concentration of from 30 to 720 μM and the ketorolac is included at a concentration of from 10 to 270 μM.

2. The dosage form of claim 1 , wherein the phenylephrine is included at a concentration of from 90 to 720 μM and the ketorolac is included at a concentration of from 44 to 134 μM.

3. The dosage form of claim 1 , wherein dosage form is stable for a period of at least 24 months when stored at a temperature of from 5+/−3° C. to 25+/−2ºC.

4. The dosage form of claim 1 , wherein the dosage form is preservative-free and antioxidant-free.

5. The dosage form of claim 4 , wherein dosage form is stable for a period of at least 24 months when stored at a temperature of from 5+/−3° C. to 25+/−2ºC.

6. The dosage form of claim 1 , wherein the buffer system is selected from a sodium phosphate buffer system and a sodium citrate buffer system.

7. The dosage form of claim 6 , wherein the buffer system comprises a sodium citrate buffer system.

8. The dosage form of claim 7 , wherein the buffer system comprises an about 20 mM sodium citrate buffer system.

9. The dosage form of claim 1 , wherein the dosage form has a pH of from 5.8 to 6.8.

10. The dosage form of claim 1 , wherein the inert gas overlay is a nitrogen gas overlay.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2024
From: RAYNER SURGICAL GROUP LIMITED
To: RAYNER INTRAOCULAR LENSES LIMITED
Reel/Frame 068708/0933 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2024
From: MACULA BIDCO LIMITED
To: RAYNER SURGICAL GROUP LIMITED
Reel/Frame 068696/0334 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2024
From: RAYNER SURGICAL (IRELAND) LIMITED
To: MACULA BIDCO LIMITED
Reel/Frame 068182/0732 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2023
From: RAYNER SURGICAL INC.
To: RAYNER SURGICAL (IRELAND) LIMITED
Reel/Frame 063880/0572 →
Continuity (13)
Continuation 17405269 · Aug 18, 2021
Continuation 17171373 · Feb 9, 2021
Continuation 16944609 · Jul 31, 2020
Continuation 16738546 · Jan 9, 2020
Continuation 16454775 · Jun 27, 2019
Continuation 16213758 · Dec 7, 2018
Continuation 15823282 · Nov 27, 2017
Continuation 15278514 · Sep 28, 2016
Continuation 14721151 · May 26, 2015
Continuation 14061039 · Oct 23, 2013
Provisional Application 61736179 · Dec 12, 2012
Provisional Application 61718026 · Oct 24, 2012
Related Publication 20220175726A1 · Jun 9, 2022